Stockscreener 앱 받기
183.41
0.60%
1.10
시간 외 거래:
187.25
3.84
+2.09%
Biogen Inc 주식(BIIB)의 최신 뉴스
Biogen’s BIIB080 Imaging Study Completes, Marking Quiet but Key Step in Alzheimer’s Pipeline - TipRanks
Biogen Targets Pediatric MS Growth With New Phase 3 Fumarate Study - TipRanks
Biogen to present litifilimab data for cutaneous lupus at AAD - Investing.com
Securities Litigation on Behalf of Purchasers of Biogen, Inc. Securities (BIIB) Certified as Class Action - GlobeNewswire Inc.
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting - Yahoo Finance
The Escalator: Biogen, Flagship Pioneering, Grail and more - Medical Marketing and Media
Insight Wealth Strategies LLC Buys Shares of 28,960 Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Shares Sold by Hudson Bay Capital Management LP - MarketBeat
Biogen Conference: Tau ASO CELIA Updates, Pre-Symptomatic Leqembi, SMA Phase 3 Plans - Yahoo Finance
Biogen Inc. stock outperforms competitors on strong trading day - MSN
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Why Biogen Inc. (BIIB) is a top value stock for the long term - MSN
Here's why Biogen Inc. (BIIB) is a strong momentum stock - MSN
Biogen at Stifel Forum: Strategic Insights on Alzheimer’s and Neuromuscular Advances - Investing.com
BIIB: Advances in Alzheimer's, SMA, and immunology pipelines highlight innovation and pivotal trials - TradingView
Biogen Inc. (NASDAQ: BIIB) Q4 2025 earnings call transcript - MSN
HSBC Maintains Reduce Rating for BIIB, Raises Price Target | BII - GuruFocus
Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, HSBC Analyst Says - MarketBeat
Biogen Legal Chief Exit Puts Focus On Valuation Gap And Returns - simplywall.st
Dow Update: Is Biogen Inc showing insider buying2026 Breakouts & Fast Momentum Entry Tips - baoquankhu1.vn
Gotham Asset Management Boosts Biogen Stake by 65% - National Today
Gotham Asset Management LLC Has $37.89 Million Position in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Stock Holdings Boosted by Brevan Howard Capital Management LP - MarketBeat
Behavioral Patterns of BIIB and Institutional Flows - Stock Traders Daily
Banco Bilbao Vizcaya Argentaria S.A. Increases Stake in Biogen Inc. $BIIB - MarketBeat
Capula Management Ltd Takes $1.43 Million Position in Biogen Inc. $BIIB - MarketBeat
Cinctive Capital Management LP Raises Stake in Biogen Inc. $BIIB - MarketBeat
Suvretta Capital Management LLC Has $23.56 Million Stake in Biogen Inc. $BIIB - MarketBeat
iSAM Funds UK Ltd Has $2.41 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Does New Once-Yearly SMA Data And Phase 3 Plan Change The Bull Case For Biogen (BIIB)? - simplywall.st
Biogen CLO Retiring After 20 Years With Biopharma Biz - Law360
Biogen's Legal Chief for 2 Decades Exiting in May - Law.com
Legal & General Group Plc Buys 146,583 Shares of Biogen Inc. $BIIB - MarketBeat
BIIB Stock Price, Quote & Chart | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Biogen Details West Coast Hub, Felzartamab Phase 3 Plans and AMR Readout Timeline at Conference - Yahoo Finance
Biogen Rare Disease Data And Valuation Discount Draw Investor Attention - Yahoo Finance
Assessing Biogen (BIIB) Valuation After Recent Shareholder Return Momentum - simplywall.st
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders - BioSpace
Biogen’s Spinraza successor benefits SMA patients unresponsive to gene therapy - Yahoo
Swiss National Bank Cuts Stake in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. Announces Departure of Chief Legal Officer Susan H. Alexander Effective May 2026 - Minichart
Biogen Inc. $BIIB Shares Sold by Dimensional Fund Advisors LP - MarketBeat
Biogen presents Phase 1b data on salanersen for SMA treatment - Investing.com South Africa
Biogen Announces Upcoming Departure of Chief Legal Officer - TipRanks
Biogen chief legal officer Susan H. Alexander to depart at end of May - Investing.com
Oppenheimer reiterates Biogen stock rating on SMA drug data By Investing.com - Investing.com Nigeria
Susan H. Alexander to Depart as Biogen Chief Legal Officer - TradingView
Oppenheimer reiterates Biogen stock rating on SMA drug data - Investing.com
Biogen (NASDAQ: BIIB) Chief Legal Officer Susan Alexander to depart - Stock Titan
Biogen Inc. Announces Departure of Chief Legal Officer Susan H. Alexander, Effective End of May 2026 - marketscreener.com
Biogen Unveils Phase III Salanersen Program To Bring Longer-Acting SMA Option - Citeline News & Insights
Biogen builds case for Spinraza successor with fresh data - BioPharma Dive
To promote Zurzuvae, Biogen and Supernus are Turning Tides against postpartum depression - Medical Marketing and Media
Biogen Stock: Is BIIB Outperforming the Healthcare Sector? - Barchart
Biogen Settles Investors' $50M Claim Over Pain Drug Deal - Law360
Biogen presents additional salanersen data in SMA - The Pharmaletter
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock - Yahoo Finance
Biogen (BIIB) Reveals Promising Phase 1b Study Results for Salan - GuruFocus
Van ECK Associates Corp Has $149.46 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen presents new Phase 1b results for spinal muscular atrophy drug at MDA Conference - Traders Union
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy - Biogen
Biogen Presents Additional Salanersen Data Showing New - GlobeNewswire
Biogen Cuts Profit Guidance After Deals to Bolster Pipeline - MSN
Biogen (BSP:BIIB34) NonCurrent Deferred Revenue : R$0 Mil (As of Dec. 2025) - GuruFocus
Biogen (WBO:BIIB) NonCurrent Deferred Revenue : €0 Mil (As of Dec. 2025) - GuruFocus
Biogen to Participate in the Stifel 2026 Virtual CNS Forum - Biogen
Therapeutics Sector Q4 2025 Earnings Review: Resilience and GrowthNews and Statistics - IndexBox
Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
Causeway Capital Management LLC Acquires 74,163 Shares of Biogen Inc. $BIIB - MarketBeat
Jefferies Financial Group Inc. Cuts Stock Holdings in Biogen Inc. $BIIB - MarketBeat
0.33%
0.99%
자본화:
|
볼륨(24시간):